STOCKWATCH
·
Biotechnology: Laboratory Analytical Instruments
Quarterly ResultMay 5, 2026, 06:17 AM

Waters Corp Q1 Revenue $1.267B, Adj EPS $2.70; Raises FY26 Guidance

AI Summary

Waters Corporation reported strong first-quarter 2026 financial results, with total reported revenue of $1.267 billion, exceeding guidance, and adjusted EPS growing 20% year-over-year to $2.70. This marks the first reporting period including the recently acquired Biosciences and Diagnostic Solutions businesses, which contributed $520 million in revenue. The company also raised its full-year 2026 organic constant currency revenue growth guidance to 6.5%-8.0% and adjusted EPS guidance to $14.40-$14.60, reflecting double-digit growth.

Key Highlights

  • Q1 2026 total reported revenue was $1.267 billion, exceeding guidance by $56 million.
  • Organic revenue grew 13% as reported and 11% in constant currency.
  • Acquired Biosciences and Diagnostic Solutions businesses generated $520 million in revenue.
  • Adjusted EPS for Q1 2026 was $2.70, a 20% increase year-over-year.
  • Full-year 2026 organic constant currency revenue growth guidance raised to 6.5% to 8.0%.
  • Full-year 2026 adjusted EPS guidance raised to $14.40 to $14.60.
  • Analytical Sciences Division revenue was $607 million, up 14% year-over-year.
  • Advanced Diagnostics Division revenue was $349 million, up 560% year-over-year.
WAT
Biotechnology: Laboratory Analytical Instruments
WATERS CORP /DE/

Price Impact